on Mar 20,2023
Feldan Therapeutics is pleased to share the promising results of FLD103 to treat basal cell carcinoma. A poster presented at the WCH23 Dermatology Conference last January (Intralesional Treatment of Basal …
Read Storyon Jan 18,2022
Quebec City, Canada, January 18, 2022 - Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the …
Read Storyon Apr 14,2021
Read more on pages 54 to 57: BIOTECanada Insights sping 2021 …
Read Storyon Apr 7,2021
Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this initiative alongside its long-standing collaborator, Dr. Paul McCray of the University of Iowa. https://www.nature.com/articles/s41586-021-03191-1 About the collaboration between Dr. McCray and Feldan Therapeutics: The lungs, …
Read Storyon Feb 9,2021
Québec, Canada, February 9, 2021 – Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J …
Read Storyon Jan 14,2021
Quebec City, Canada, January 14, 2021 – Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation …
Read Storyon Jun 16,2020
Quebec City, Canada, June 16, 2020, Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. Robert …
Read Storyon Oct 28,2019
Dr. Paul McCray (University of Iowa) and Feldan Therapeutics enable protein and CRISPR nuclease delivery to cultured human well-differentiated airway epithelial cells and in vivo using the Feldan Shuttle technology …
Read Storyon Jun 14,2019
On June 13th 2019, Anges Québec celebrated its 10th anniversary as part of the annual Rendez-vous 2019, the event that brings together angel investors, portfolio companies, venture capital ecosystem players …
Read Storyon Jun 4,2019
Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to …
Read Story
2666, Boul. du Parc Technologique Suite 290
Quebec, Qc, Canada,
G1P 4S6
Phone: 1-418-872-7277
Email: info@feldan.com